In CLL, the alteration of miRNA profiles led to the development of Bcl2 inhibitors and anti-ROR1 antibodies, and more targets are currently being studied not only for CLL but also for other malignancies. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.